Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article.
PMID: 34954390
2022
Infection, genetics and evolution
Abstract: HBV polymerase rtV173L, rtL180M, and rtM204V major substitutional mutations were identified.
Dried blood spot sampling for hepatitis B virus quantification, sequencing and mutation detection.
Abstract: An HIV-coinfected patient presented the rtM204V/I-rtL180M double resistance mutation in serum and DBS.
Result: One patient had the double resistance polymerase mutation rtM204V/I-rtL180M, in both serum and DBS.
Table: M204V
Discussion: Regarding resistance mutations, the double rtM204V/I-rtL180M mutation in polymerase gene (to lamivudine, telbivudine and entecavir:partial) was observed in both serum and DBS samples from an
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient.
Abstract: As a result, our study revealed that rtL180M (M) and rtM204V (V) mutations, already known as lamivudine-resistant mutations, confer resistance to BSV in the CHB patient.
Abstract: The ten mutations include rtV23I (I), rtH55R (R), rtY124H (H), rtD134E (E), rtN139K (K), rtL180M (M), rtM204V (V),
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.
Introduction: In contrast, the HBV variant with three mutations in the polymerase gene (rtV173L + rtL180M + rtM204V), also generating the G145R mutation in S-HBsAg due to overlapping reading frames, was stable.
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Abstract: The most frequently encountered RAMs are M204V/I: 48.8%, L180M: 33.3%, L80V: 28.8%, and V173L: 42.2%.
Result: M204V/I: 48.8%, plus L180M: 33.3% +- L80V: 28.8% and V173L: 42.2%:a profile suggestive for LAM resistance (with all mutations, except for M204V, also being associated with telbivudine resistance, and the combination of L180M, M204V, andV173L being associated with entecavir (ETV) resistance.
Discussion: In our study, despite the frequent association of the primary resistance mutations M204V/I with the compensatory
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Abstract: APPROACH AND RESULTS: In this study, we retrospectively monitored the emergence and reversion of the rtM204I/V mutant, a signature lamivudine resistance (LAMR ) mutation serving as a biomarker of cccDNA turnover in liver biopsies and longitudinal serum samples from two clinical trials.
Method: Percentage Composition of rtM204I/V in HBV cccDNA, Viral DNA, and RNA.
Method: Percentages of rtM204I/V mutations were calculated using Sequencher software (Gene Codes, Ann Arbor, MI).
Method: To exclude the potential impact of adefovir on the evolution of drug resistance mutation, only those patients from the MONO group who developed the signature rtM204I/V mutation durin
Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
Abstract: E-CFCP also reduced HBVETV-RL180M/S202G/M204V-viremia by 2 logs over 2 weeks, while ETV completely failed to reduce HBVETV-RL180M/S202G/M204V-viremia.
Abstract: RESULTS: E-CFCP potently blocked HBVWTD1 production (IC50qPCR_cell=1.8 nM) in HepG2.2.15 cells and HBVWTC2 (IC50SB_cell=0.7 nM), entecavir (ETV)-resistant HBVETV-RL180M/S202G/M204V (IC50SB_cell=77.5 nM), and adefovir-resistant HBVADV-RA181T/N236T production (IC50SB_cell=14.1 nM) in Huh7 cells.
Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria.
Abstract: HBV DRMs V173L, L180M, S202I and M204V/I, which are associated with lamivudine resistance, were detected in 32.2% (n = 10/31) of the HBV DNA-positive samples.
Result: Amino acid substitutions were detected in the following frequency: rtM204V/I (9/31; 29.0%), rtL180M (8/31; 25.8%), rtV173L (7/31; 22.5%).
Result: No single mutation was detected while all amino acid substitutions were detected in combinations as rtL180M + rtV173L + rt
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
Abstract: Four mutations (rtS106C, rtD134N/S[N/S], rt
HBV mutation literature information.
PMID: 
2022
Infection, genetics and evolution
Browser Board
Co-occurred Entities
Filtrator
ViMRT